455 Mission Bay Boulevard South
Tel: 415-482-5300, Toll Free 855-482-NKTR (6587)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
311 articles with Nektar Therapeutics
It has been a busy month for San Francisco-based Nektar Therapeutics. It started with a partnership to pair its lead drug candidate with one developed by pharma giant Pfizer. On Wednesday, the company named a Genentech veteran to helm its oncology programs.
Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs
Dr. Lin will lead development strategy and study oversight of the company's immuno-oncology candidates and other oncology programs.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR
Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers.
Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018.
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
Nektar Therapeutics announced that it has entered into an oncology clinical collaboration with Pfizer Inc. to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN).
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting
Nektar Therapeutics announced today that it will webcast an analyst and investor conference call with melanoma specialists and company management on Saturday, November 10, 2018 at 9:00 a.m. EST in Washington, D.C. during the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
11/2/2018Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!
Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018,
10/9/2018Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
Block & Leviton LLP is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers and directors violated federal securities laws.
Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held from November 7 to November 11, 2018, at the Walter E. Washington Convention Center in Washington, D.C.
Nektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham
Nektar Therapeutics (Nasdaq: NKTR) today announced that it has appointed Karin Eastham as an independent director to its Board of Directors.
9/5/2018Summer is coming to an end, but the job front is still sizzling. Check out the top companies who are looking for candidates like you right now!
Nektar Therapeutics reported its financial results for the second quarter ended June 30, 2018.
Nektar to Announce Financial Results for the Second Quarter 2018 on Wednesday, August 8, 2018, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
NKTR-181 is a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
Martin Shkreli has been blogging about the biopharma industry from prison.
Program will Aim to Further Characterize the Functional Impact of Nektar Immunotherapies